Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load

Inclusion Criteria: * Patients with myelodysplastic syndrome with an IPSS score being Intermediate-1 or low. * Patients who already received ≥20 unit (100 mL/kg) of packed red blood cells and showing evidence of iron overload (serum ferritin \>1000 µg/L). * Patients post stem cells transplantation with disease recurrence with MDS IPSS score low or intermediate 1. * Patients who have given consent personally in writing Exclusion Criteria: * Patients with myelodysplastic syndrome with an IPSS score being Intermediate-2 or High. * Patients with serum creatinine \>2.0 x ULN * Patients with ALT(SGPT) levels \> 5 x ULN * Significant proteinuria as indicated by a urinary protein/creatinine ratio \>0.5 mg/mg in a non-first void urine sample on two assessments during the screening period. * History of HIV positive test result. When there are any signs or symptoms indicative of the disease even if the diagnosis is not made, additional test should be conducted. * History of clinical or laboratory evidence of active Hepatitis B or Hepatitis C (HBsAg in the absence of HBsAb OR HCV Ab positive with HCV RNA positive and ALT above the normal range) * Patients with systemic uncontrolled hypertension * Patients with unstable cardiac disease not controlled by standard medical therapy * Systemic disease (cardiovascular, renal, hepatic, etc.) which would prevent study treatment * Pregnancy or breast feeding. Female of child-bearing potential should conduct contraception during the clinical trial. * Patients treated with systemic investigational drug within the past 4 weeks or topical investigational drug within the past 7 days * Other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug * Patients being considered by the investigator potentially unreliable and/or not cooperative with regard to the study protocol * History of hypersensitivity to any of the study drug or excipients